首页> 外文期刊>Nuclear Medicine and Biology >A change of in vivo characteristics depending on specific activity of radioiodinated (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-pIV] as a ligand for sigma receptor imaging
【24h】

A change of in vivo characteristics depending on specific activity of radioiodinated (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-pIV] as a ligand for sigma receptor imaging

机译:体内特征的变化取决于放射性碘化(+)-2- [4-(4-碘苯基)哌啶子基]环己醇[(+)-pIV]作为σ受体成像配体的比活

获取原文
获取原文并翻译 | 示例
       

摘要

The radioiodinated (+)-p-iodovesamicol [(+)-pIV], which shows a high binding affinity for sigma-1 (sigma-1) receptors, is prepared by an exchange reaction. The specific activity (SA) is fairly low and therefore is insufficient for clinical use. In this study, we prepared (+)-[I-125]pIV with a high SA from tributylstannyl precursor and compared the in vivo characteristics between high and low SA by imaging sigma-1 receptors in the central nervous system. In the biodistribution study, a difference in brain accumulation was observed between the two methods. At 30 min postinjection, the brain accumulation (1.58%ID/g) of low SA [0.6-1.1 TBq/mmol (16-30 Ci/mmol)] (+)-[I-125]pIV was higher than that (1.34%ID/g) of high SA [>88.8 TBq/mmol (>2400 Ci/mmol)] (+)-[I-125]pIV. In the blocking study, the brain uptake of high SA (+)-[I-125]pIV was reduced more significantly by the coadministration of sigma ligands such as pentazocine, haloperidol or SA4503 than that of low SA (+)[I-125]pIV These results showed that nonspecific binding of high SA (+)-[I-125]pIV in the brain was lower than that of low SA (+)-[I-125]pIV, and high SA (+)-[I-125]pIV bound more specifically to (sigma-1 receptors in the brain than low SA (+)-[I-125]pIV. In contrast, in the blood-binding study, high SA (+)-[I-125]pIV (58.4%) bound to blood cells with higher affinity than low SA (+)-[I-125]pIV (46.0%). In metabolite studies, blood metabolites of high SA (+)-[I-125]pIV (57.3+/-3.5%) were higher than those of low SA (+)-[I-125]pIV (45.5+/-4.1%) at 30 min postinjection. Higher SA may be apt to bind to blood cells with higher affinity and to be metabolized faster. (C) 2008 Elsevier Inc. All rights reserved.
机译:通过交换反应制备对sigma-1(sigma-1)受体具有高结合亲和力的放射性碘(+)-对碘维他命[[+]-pIV]。比活性(SA)相当低,因此不足以用于临床。在这项研究中,我们从三丁基锡烷基前体制备了具有高SA的(+)-[I-125] pIV,并通过对中枢神经系统中的sigma-1受体进行成像,比较了高SA和低SA之间的体内特征。在生物分布研究中,在两种方法之间观察到脑积聚的差异。注射后30分钟,低SA [0.6-1.1 TBq / mmol(16-30 Ci / mmol)](+)-[I-125] pIV的脑蓄积(1.58%ID / g)高于(1.34高SA [> 88.8 TBq / mmol(> 2400 Ci / mmol)](+)-[I-125] pIV的%ID / g)。在这项阻断研究中,与低SA(+)[I-125]相比,戊二胺,氟哌啶醇或SA4503等sigma配体的共同给药可显着降低高SA(+)-[I-125] pIV的大脑摄取。 ] pIV这些结果表明,大脑中高SA(+)-[I-125] pIV的非特异性结合低于低SA(+)-[I-125] pIV和高SA(+)-[与低SA(+)-[I-125] pIV相比,I-125] pIV与(sigma-1受体在大脑中的结合更明确。相反,在血液结合研究中,高SA(+)-[I- 125] pIV(58.4%)以比低SA(+)-[I-125] pIV(46.0%)高的亲和力与血细胞结合。在代谢物研究中,高SA(+)-[I-125]的血液代谢物在注射后30分钟,pIV(57.3 +/- 3.5%)高于低SA(+)-[I-125] pIV(45.5 +/- 4.1%),较高的SA可能易于与(C)2008 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号